Chat with us, powered by LiveChat

 Speaker Profile

M.D., Ph.D., President & CEO, Ultragenyx

Biography
A medical geneticist by training, Dr. Kakkis is a pioneer in the development and commercialization of treatments for rare diseases. He is founder and CEO at Ultragenyx, a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases. The company has three approved therapies and holds ex-US rights to a fourth approved product, and a deep pipeline of potential treatments across a variety of therapeutic modalities including gene therapy, mRNA therapy, biologics, and small molecule. Before founding Ultragenyx in 2010, Dr. Kakkis guided and contributed to the development of multiple approved rare disease products as chief medical officer at BioMarin Pharmaceutical. Dr. Kakkis also founded and serves on the Board of EveryLife Foundation for Rare Diseases, a non-profit dedicated to accelerating innovation for rare diseases. Dr. Kakkis has been recognized for his leadership by Biotechnology Innovation Organization (BIO), the National MPS Society, WORLDSymposium, and California Life Sciences.


 Session Abstract – PMWC 2023 Silicon Valley

Track 1 - January 25 9.00 A.M.-4.15 P.M.


Track Co-Chairs:
Yael Weiss, Mahzi
Peter Marks, FDA

  • Welcome and Opening by Track Chairs: Yael Weiss, Mahzi
  • PMWC 2023 Luminary Award Ceremony
    - Allyson Berent, Angelman Foundation
    - Terry Pirovolakis, CureSPG50
  • From Bench to Bedside - Biomarkers, Natural History Studies, Animal Models (PANEL)
    Chair: Peter Marks, FDA (Allyson Berent, FAST)
    - Emil Kakkis, Ultragenyx
    - Alysson Muotri, UCSD
    - Nasha Fitter, Invitae
  • Commercialization - Moving from Rare to Common (PANEL)
    Chair: Matthew Patterson, Vor Bio
    - Shankar Ramaswamy, Kriya
    - Rahul Singhvi, Resilience
    - Sarah Glass, Ultragenyx
    - Andrew Lo, MIT
    - Mark Harrison, University of British Colombia
  • Future Modalities (PANEL)
    Chair: Shannon Muir, CIAPM
    - Nadav Ahituv, UCSF
    - Amber Salzman, Epic Bio
    - Ben Oakes, Scribe Therapeutics
  • PMWC NCI Showcase
    - Michael M. Binkley, OpenCell
  • Cellular Rejuvenation Programming
    - Hana El-Samad, UCSF
  • Bioethics & Ethical Implications in Cell and Gene Therapies
    - Hank Greely, Stanford
  • Patient Driven Therapies: The Challenges and Successes (PANEL)
    Chair: Yael Weiss, Mahzi
    - Terry Pirovolakis, CureSPG50
    - Allyson Berent, Angelman Foundation
  • PMWC Showcase - Peter Marinkovich, Stanford

PMWC 2027 Silicon Valley - Program

PMWC Hall of Impact

Previous Speakers Include

Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.

×

Add Names/PO on Receipt

Request Atul Butte Company Competition Submission Form

Fields marked with an * are required

Contact Us:

Fields marked with an * are required 

Save $1301 By AUG. 27
PMWC 2027 Jan. 27-29 • Santa Clara
15 tracks • 400 speakers Co-hosted by Stanford/UCSF/Yale • Davos of PM
SAVE $1301 Rate increases AUG. 27 LOCK IN RATE

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required

Apply to Speak at PMWC Silicon Valley by AUG. 27TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.